Effectivity and Safety of Endoscopic Ultrasonography-guided Laser Ablation for Refractory Neoplasms

First Affiliated Hospital of Zhejiang University1 site in 1 country80 target enrollmentMay 2016

ConditionsRefractory Neoplasms

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Refractory Neoplasms
Sponsor: First Affiliated Hospital of Zhejiang University
Enrollment: 80
Locations: 1
Primary Endpoint: 80 patients of refractory neoplasms with EUS-guided laser ablation-related effectivity as assessed by MRI
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of endoscopic ultrasonography (EUS) guided laser ablation liver, pancreas, and retroperitoneal tumors, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.

Registry

clinicaltrials.gov

Start Date

May 2016

End Date

June 2018

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

First Affiliated Hospital of Zhejiang University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with refractory neoplasms including small hepatocellular carcinoma adjacent to the gastrointestinal tract, pancreatic neuroendocrine tumor, retroperitoneal tumor with less than 3 cm in diameter;
•Patients with Child-Pugh A/B;
•Patients with PLT ≥ 50\*10E9/L and PT ≤ 20s.

Exclusion Criteria

•Patients with severe cardiopulmonary disease, intolerant endoscopy and anesthesia, upper gastrointestinal bleeding in shock, corrosive esophagitis and acute gastritis.